Details of the Drug

General Information of Drug (ID: DMIEPJG)

Drug Name

BTT-1023

Synonyms

SI-3106; SI-636; Fully human VAP-1 mAbs (inflammation), BioTie/Seikagaku; Fully human VAP-1 monoclonal antibody (inflammation), BioTie/Seikagaku; VAP-1 antibody (rheumatoid arthritis/psoriasis), BioTie

Indication

Disease Entry	ICD 11	Status	REF
Psoriasis vulgaris	EA90	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

TTD ID: D06GUG

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Membrane copper amine oxidase (AOC3)	TT7HC21	AOC3_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Psoriasis vulgaris

ICD Disease Classification

EA90

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Membrane copper amine oxidase (AOC3)	DTT	AOC3	8.36E-22	-1.03	-1.54

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT02239211) A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis. U.S. National Institutes of Health.
2	Preclinical evaluation of a radioiodinated fully human antibody for in vivo imaging of vascular adhesion protein-1-positive vasculature in inflammation. J Nucl Med. 2013 Aug;54(8):1315-9.